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Background: Optimal control of leucine concentrations in MSUD dis-
ease is essential for maximising neurocognitive outcomes. In 2014
Frazier et al. published guidelines recommending lowering the leucine
treatment range to 75–200 μmol/L for patients ≤5 years and 75–
300 μmol/L for >5 years. In 2013, the UK Expanded Newborn
Screening (ENBS) guidelines recommended the range 200–
400 μmol. In 2015, this was later reduced to 150–300 μmol/L and
reported the typical leucine intake for classical MSUD as 300 mg/day
(6 × 50 mg leucine exchanges). We have adopted these guidelines for
our MSUD patients aged 5 years and under.
Aim: To audit leucine monitoring results to determine if the lower treatment
range was achievable.
Methods: A 12 month retrospective review of all blood spot leucine levels
(including during illness), number of 50 mg leucine exchanges per day and
frequency of samples. All classical MSUD patients 5 years and under were
included.
Results: Six patients were identified (median age 4.75 years, range 0.7–8
years). All diagnosed in the neonatal period (median age 13 days, range 7–
17 days), median screening level 3635 (range 1153–4600 μmol/L). The mean
of each patient’s 12 month leucine monitoring results was determined (median
210, range 178–290 μmol/L). The proportion of leucine concentrations below
300 μmol/L for each patient was also determined (median 75 %, range 60–
92%). Themedian number of samples per patient received in 52weekswas 64
(range 37–76). The median number of mean 50 mg leucine exchanges per day
for each patient was 7 (range 5–13). The median peak leucine level during
illness was 765 (range 554–895 μmol/L).
Discussion: Our data shows that the UK ENBS lower treatment range of 150–
300 μmol/L is achievable without having to overly restrict leucine exchanges.
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Background: Maleic aciduria leading to a diagnosis of maleylacetoacetate
isomerase (MAAI) deficiency.
Case Report: An 18 month old girl with developmental delay, difficult behav-
iour, irritability and autistic features.
Results: Urine organic acids showed hydroxyketoheptanoate,
diketoheptanoate and a trace of succinylacetone (SA). Further investigation
for tyrosinaemia type 1 showed normal amino acids, liver function tests and
coagulation. AFP was slightly increased (21kU/L: normal < 10) but lectin
reactive-AFP was normal. Liver and brain MRI showed no significant find-
ings. Plasma SA and urine 5-aminolevulinic acid were slightly increased
(2.20umol/L; ref range < 0.1 & 22.1umol/mmol creat; ref range < 5.2 respec-
tively). Apart from SA and metabolites, urine organic acids showed no phe-
nolic acids but maleic acid was increased. Fibroblast fumaryl
acetoacetase and sequencing of the FAH gene were normal. Treatment
with low dose nitisinone (0.15 mg/kg/day) and a low tyrosine diet were
commenced. The biochemical abnormalities resolved except AFP which
remained slightly increased.
The biochemical findings suggested MAAI deficiency due to a defect in the
GSTZ1 gene. The Illumina HiSeq platform was used to sequence the gene
captured by the TruSight One Panel target enrichment system (Illumina).
Analysis was performed with an in-house pipeline. Quality analysis of cover-
age data revealed a pattern consistent with a homozygous deletion of exons 3,
4, 5 and 6. This was confirmed by targeted microarray analysis (Affymetrix
CytoScan HD array). This deletion has not been previously described in the
literature or in any database; as it removes a big part of the gene it is likely to be
pathogenic.
Discussion: Although it is not clear whether MAAI deficiency has caused the
neurodevelopmental problems, this case adds to our knowledge of the pheno-
type of MAAI deficiency.
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Background: Over the last few years, microdeletions of the 22q11.2 region
responsible for DiGeorge syndrome, or velocardiofacial syndrome, have been
increasingly related to neuropsychiatric disorders including schizophrenia and
bipolar disorders. These signs seem to be related to certain genes located in the
hemideleted region as the proline dehydrogenase (PRODH) and the catechol-
o-methyltransferase (COMT) genes. The PRODH or proline oxidase deficien-
cy is responsible for hyperprolinemia type 1 (HPI) also causing psychiatric
manifestations.
Case Report: We describe a 17 year old boy with previous mild psychomotor
and speech delay, mild cognitive impairment, and obsessive behaviours who
started his adolescent psychiatric care presenting irritable mood and aggressive
behaviour with schizophrenia symptoms that scored a “severely ill” level
PANSS assessment. Symptoms got worse when he was treated with valproic
acid and plasma aminoacids showing increase in alanine and proline, sug-
gested a mitochondrial involvement of the proline metabolic pathway.
Results: Mild dysmorphia suggested a possible 22q11.2 deletion genetically
confirmed involving both the PRODH and COMT regions. HPI that can pres-
ent with psychiatric features is however a recessive disorder and therefore the
symptoms could not be solely explained by this genetic deletion. Additional
investigations also showed disclosed a p.L289m (c.1865 T > A) mutation in
the PRODH gene.
Discussion: We believe that the association of this mutation together with the
22q11.2 deletion would lead to a decrease of functional protein. Although it may
be difficult to diagnosis chromosomal abnormalities in patients with no clear
malformations and mild dysmorphic features as in this patient we emphasize
need to investigate the aetiology in patients with psychiatric symptoms, especial-
ly if they have other systemic manifestations such as developmental delay or
psychotic symptoms, as it may be important in the management of the patients.
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